S
BMY.RT

Seeyond’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Seeyond’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,786
Closed -$7K – 606
2020
Q4 		$7K Hold
10,786
– – ﹤0.01% 602
2020
Q3 		$24K Buy
10,786
+249
+2% +$711 ﹤0.01% 600
2020
Q2 		$38K Sell
10,537
-5,651
-35% -$20.4K ﹤0.01% 599
2020
Q1 		$2.65M Hold
16,188
– – 0.37% 51
2019
Q4 		$49K Buy
+16,188
New +$42.1K 0.01% 628

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Seeyond's BMY.RT Position: Q1 2021 in Review

Seeyond sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,786 shares — an estimated $7K sold.

Seeyond first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2.65M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Seeyond reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Seeyond sold 10,786 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $7K.
  • Seeyond first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Seeyond's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.65M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Seeyond's 13F filing for Q1 2021, filed 14 May 2021.